Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

Analysts Cut Price Target On MEI Pharma As Stock Falls To 52-Week Low After Zandelisib Update

Published 25/03/2022, 18:47
© Reuters.  Analysts Cut Price Target On MEI Pharma As Stock Falls To 52-Week Low After Zandelisib Update
MEIP
-
TGTB34
-

The FDA crushed MEI Pharma Inc's (NASDAQ: MEIP) hopes of winning accelerated approval for its PI3K inhibitor, zandelisib, on the strength of phase 2 data.

  • In the meeting, the FDA informed that a randomized clinical trial is "needed to adequately assess drug efficacy and safety of PI3K inhibitor drug candidates, including zandelisib."
  • The FDA is set to hold an advisory committee meeting next month to discuss the need for randomized data on PI3K inhibitors.
  • The companies do not plan to submit an FDA marketing application based on the single-arm Phase 2 TIDAL study and will continue with the randomized Phase 3 COASTAL study as planned.
  • Working with its partner Kyowa Kirin, MEI linked zandelisib to a 70.3% response rate in follicular lymphoma patients in a Phase 2 trial.
  • Stifel downgraded MEI Pharma to Hold from Buy with a price target of $2, down from $6.
  • Jefferies downgraded the company to Hold from Buy with a price target of $1, down from $4.
  • H.C. Wainwright reduced the price target to $5 from $10.
  • Truist lowered the price target to $3 from $8, and BTIG cut the price target to $4 from $11 on MEIP stock.
  • Price Action: MEIP shares are down 63% at $0.67 during the market session on the last check Friday.
Latest Ratings for MEIP DateFirmActionFromTo
Feb 2022JefferiesInitiates Coverage OnBuy
May 2020SunTrust Robinson HumphreyInitiates Coverage OnBuy
Feb 2019BTIGInitiates Coverage OnBuy
View More Analyst Ratings for MEIP

View the Latest Analyst Ratings

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read at Benzinga

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.